Variability in aggregometry response before and after initiation of clopidogrel therapy

References

• Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med. 2001; 345:494–502.
   PubMed Web of Science ®Google Scholar
• Mehta SR, Yusuf S, Peters RJ, Bertrand ME, Lewis BS, Natarajan MK, Malmberg K, Rupprecht H-J, Zhao F, Chrolavicius S, Copland I, Fox KAA. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet. 2001; 358:527–33.
   PubMed Web of Science ®Google Scholar
• Steinhubl SR, Berger PB, Mann JT III, Fry ETA, DeLago A, Wilmer C, Topol EJ. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA. 2002; 288:2411–20.
   PubMed Web of Science ®Google Scholar
• Rocca B, Patrono C. Determinants of the inter individual variability in response to antiplatelet drugs. J Thromb Haemost. 2005; 3:1597–602.
   PubMed Web of Science ®Google Scholar
• Cattaneo M. Resistance to antiplatelet drugs: molecular mechanisms and laboratory detection. J Thromb Haemost. 2007; 5Suppl. 1:230–7.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Aspirin and clopidogrel resistance: consideration and management. J Interv Cardiol. 2006; 19:439–48.
   PubMedGoogle Scholar
• Lerkevang GE, Hvas A-M, Kristensen SD. Aspirin resistance: myth or major problem?. Scand J Clin Lab Invest. 2008; 68:257–9.
   PubMedGoogle Scholar
• Gurbel PA, Tantry US. Clopidogrel resistance?. Thromb Res. 2007; 120:311–21.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Sabatè M, Banüelos C, Hernández-Antolin R, Escaned J, Moreno R, Alfonso F, Macaya C. High clopidogrel loading dose during coronary stenting: effects on drug response and interindividual variability. Eur Heart J. 2004; 25:1903–10.
   PubMed Web of Science ®Google Scholar
• Kastrati A, von BN, Joost A, Pogatsa-Murray G, Gorchakova O, Schomig A. Loading with 600 mg clopidogrel in patients with coronary artery disease with and without chronic clopidogrel therapy. Circulation. 2004; 110:1916–9.
   PubMed Web of Science ®Google Scholar
• Muller I, Seyfarth M, Rudiger S, Wolf B, Pogatsa-Murray G, Schömig A, Gawaz M. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart. 2001; 85:92–3.
   PubMed Web of Science ®Google Scholar
• von BN, Taubert D, Pogatsa-Murray G, Schomig E, Kastrati A, Schomig A. Absorption, metabolization, and antiplatelet effects of 300-, 600-, and 900-mg loading doses of clopidogrel: results of the ISAR-CHOICE (Intracoronary Stenting and Antithrombotic Regimen: Choose Between 3 High Oral Doses for Immediate Clopidogrel Effect) Trial. Circulation. 2005; 112:2946–50.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Tantry US. Drug insight: Clopidogrel nonresponsiveness. Nat Clin Pract Cardiovasc Med. 2006; 3:387–95.
   PubMedGoogle Scholar
• Lau WC, Gurbel PA. Antiplatelet drug resistance and drug-drug interactions: role of cytochrome P450 3A4. Pharmacological Research. 2006; 23:2691–2708.
   Google Scholar
• Cesari F, Marcucci R, Caporale R, Panniccia R, Romano E, Gensini GF, Abbate R, Gori AM. Relationship between high platelet turnover and platelet function in high-risk patients with coronary artery disease on dual antiplatelet therapy. Thromb Haemost. 2008; 99:930–5.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramirez C, Cavallari U, Trabetti E, Sabaté M, Jiminez-Quevedo P, Hernández R, Moreno R, Escaned J, Alfonso F, Banuelos Costa MA, Bass TA, Pignatti PF, Macaya C. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res. 2005; 116:491–7.
   PubMed Web of Science ®Google Scholar
• Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny J-L, Aiach M, Gaussem P. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation. 2003; 108:989–95.
   PubMed Web of Science ®Google Scholar
• Angiolillo DJ, Bernardo E, Palazuelos J, Desai B, Weisberg I, Alfonso F, Guzman LA, Hernandez-Antolin R, Zenni MZ, Macaya C, Fernandez-Ortiz A, Bass TA. Functional impact of high clopidogrel maintenance dosing in patients undergoing elective percutaneous coronary interventions. Results of a randomized study. Thromb Haemost. 2008; 99:161–8.
   PubMed Web of Science ®Google Scholar
• Bliden KP, DiChiara J, Tantry US, Bassi AK, Chaganti SK, Gurbel PA. Increased risk in patients with high platelet aggregation receiving chronic clopidogrel therapy undergoing percutaneous coronary intervention: is the current antiplatelet therapy adequate?. J Am Coll Cardiol. 2007; 49:657–66.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, Hiatt BL, O'Connor CM. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation. 2003; 107:2908–13.
   PubMed Web of Science ®Google Scholar
• Matetzky S, Fefer P, Shenkman B, Varon D, Savion N, Hod H. Effectiveness of reloading to overcome clopidogrel nonresponsiveness in patients with acute myocardial infarction. Am J Cardiol. 2008; 102:524–9.
   PubMedGoogle Scholar
• Serebruany VL. The ‘clopidogrel resistance’ trap. Am J Cardiol. 2007; 100:1044–6.
   PubMed Web of Science ®Google Scholar
• Snoep JD, Hovens MM, Eikenboom JC, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: a systematic review and meta-analysis. Am Heart J. 2007; 154:221–31.
   PubMed Web of Science ®Google Scholar
• Dropinski J, Jakiela B, Sanak M, Wegrzyn W, Biernat M, Dziedzina S, Plutecka H, Szczeklik . The additive antiplatelet action of clopidogrel in patients with coronary artery disease treated with aspirin. Thromb Haemost. 2007; 98:201–9.
   PubMedGoogle Scholar
• Eikelboom JW, Hankey GJ, Thom J, Claxton A, Yi Q, Gilmore G, Staton J, Barden A, Norman PE. Enhanced antiplatelet effect of clopidogrel in patients whose platelets are least inhibited by aspirin: a randomized crossover trial. J Thromb Haemost. 2005; 3:2649–55.
   PubMed Web of Science ®Google Scholar
• Frelinger AL III, Furman MI, Linden MD, Li Y, Fox ML, Barnard MR, Michelson AD. Residual arachidonic acid-induced platelet activation via an adenosine diphosphate-dependent but cyclooxygenase-1- and cyclooxygenase-2-independent pathway: a 700-patient study of aspirin resistance. Circulation. 2006; 113:2888–96.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Bliden KP, DiChiara J, Newcomer J, Weng W, Neerchal NK, Gesheff T, Chaganti SK, Etherington A, Tantry US. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007; 115:3156–64.
   PubMed Web of Science ®Google Scholar
• Lev EI, Patel RT, Maresh KJ, Guthikonda S, Granada J, DeLao T, Bray PF, Kleiman NS. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol. 2006; 47:27–33.
   PubMed Web of Science ®Google Scholar
• Ohmori T, Yatomi Y, Nonaka T, Kobayashi T, Madoiwa S, Mimuro J, Ozaki Y, Sakata Y. Aspirin resistance detected with aggregometry cannot be explained by cyclooxygenase activity: involvement of other signaling pathway(s) in cardiovascular events of aspirin-treated patients. J Thromb Haemost. 2006; 4:1271–8.
   PubMed Web of Science ®Google Scholar
• Patrono C, Coller B, FitzGerald GA, Hirsh J, Roth G. Platelet-active drugs: the relationships among dose, effectiveness, and side effects: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004; 1263 Suppl.:234S–264S.
   PubMed Web of Science ®Google Scholar
• Meen O, Brosstad F, Khiabani H, Gjertsen E, Lauritsen ME, Pedersen TM, Bjørnsen S, Schjelderup NM, Ameln W, Chye E, Wettergren M, Siddique SP, Erikssen G. No case of COX-1-related aspirin resistance found in 289 patients with symptoms of stable CHD remitted for coronary angiography. Scand J Clin Lab Invest. 2007; 67:1–10.
   PubMedGoogle Scholar
• Mortensen J, Poulsen TS, Grove EL, Refsgaard J, Ladefoged Nielsen H, Bendesgaard Pederesen S, Sommer Thygesen S, Hvas A-M, Dalby Kristensen S. Monitoring aspirin therapy with the Platelet Function Analyzer-100. Scand J Clin Lab Invest. 2008; 68:786–92.
   PubMed Web of Science ®Google Scholar
• Geiger J, Teichmann L, Grossmann R, Aktas B, Steigerwald U, Walter U, Schinzel R. Monitoring of clopidogrel action: comparison of methods. Clin Chem. 2005; 51:957–65.
   PubMed Web of Science ®Google Scholar
• Gurbel PA, Becker RC, Mann KG, Steinhubl SR, Michelson AD. Platelet function monitoring in patients with coronary artery disease. J Am Coll Cardiol. 2007; 50:1822–34.
   PubMed Web of Science ®Google Scholar
• Breddin HK. Can platelet aggregometry be standardized?. Platelets. 2005; 16:151–8.
   PubMed Web of Science ®Google Scholar
• Opper C, Weiner N, Xu F, Adam W, Fruhstorfer H, Wesemann W. Daily variations of functional parameters and density distribution in human blood platelets. Chronobiol Int. 1994; 11:309–19.
   PubMed Web of Science ®Google Scholar
• Muller I, Besta F, Schulz C, Massberg S, Schonig A, Gawaz M. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost. 2003; 89:783–7.
   PubMed Web of Science ®Google Scholar
• Macchi L, Christiaens L, Brabant S, Sorel N, Allal J, Mauco G, Brizard A. Resistance to aspirin in vitro is associated with increased platelet sensitivity to adenosine diphosphate. Thromb Res. 2002; 107:45–9.
   PubMed Web of Science ®Google Scholar
• Sibbing D, von BO, Schomig A, Kastrati A, von BN. Platelet function in clopidogrel-treated patients with acute coronary syndrome. Blood Coagul Fibrinolysis. 2007; 18:335–9.
   PubMed Web of Science ®Google Scholar
• Braun OO, Amisten S, Wihlborg AK, Hunting K, Nilsson D, Erlinge D. Residual platelet ADP reactivity after clopidogrel treatment is dependent on activation of both the unblocked P2Y(1) and the P2Y (12) receptor and is correlated with protein expression of P2Y (12). Purinergic Signal. 2007; 3:195–201.
   PubMed Web of Science ®Google Scholar